Advice

following a full submission:

testosterone undecanoate (Nebido) is accepted for use within NHSScotland as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Compared with alternative intramuscular preparations it offers the advantage of reduced frequency of dosing with less inter-dose fluctuation of testosterone levels.

Download detailed advice83KB (PDF)

Download

Medicine details

Medicine name:
testosterone undecanoate (Nebido)
SMC ID:
308/06
Indication:
as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Pharmaceutical company
Bayer plc/Bayer Schering Pharma
BNF chapter
Endocrine system
Submission type
Full
Status
Accepted
Date advice published:
09 March 2009